These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 15081002)

  • 1. Potent small molecule CCR1 antagonists.
    Kath JC; Brissette WH; Brown MF; Conklyn M; DiRico AP; Dorff P; Gladue RP; Lillie BM; Lira PD; Mairs EN; Martin WH; McElroy EB; McGlynn MA; Paradis TJ; Poss CS; Stock IA; Tylaska LA; Zheng D
    Bioorg Med Chem Lett; 2004 May; 14(9):2169-73. PubMed ID: 15081002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The discovery of structurally novel CCR1 antagonists derived from a hydroxyethylene peptide isostere template.
    Kath JC; DiRico AP; Gladue RP; Martin WH; McElroy EB; Stock IA; Tylaska LA; Zheng D
    Bioorg Med Chem Lett; 2004 May; 14(9):2163-7. PubMed ID: 15081001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-activity relationships of novel, highly potent, selective, and orally active CCR1 antagonists.
    Xie YF; Lake K; Ligsay K; Komandla M; Sircar I; Nagarajan G; Li J; Xu K; Parise J; Schneider L; Huang D; Liu J; Dines K; Sakurai N; Barbosa M; Jack R
    Bioorg Med Chem Lett; 2007 Jun; 17(12):3367-72. PubMed ID: 17446072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CCR1 antagonists for the treatment of autoimmune diseases.
    Gladue RP; Zwillich SH; Clucas AT; Brown MF
    Curr Opin Investig Drugs; 2004 May; 5(5):499-504. PubMed ID: 15202722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel CCR1 antagonists with oral activity in the mouse collagen induced arthritis.
    Revesz L; Bollbuck B; Buhl T; Eder J; Esser R; Feifel R; Heng R; Hiestand P; Jachez-Demange B; Loetscher P; Sparrer H; Schlapbach A; Waelchli R
    Bioorg Med Chem Lett; 2005 Dec; 15(23):5160-4. PubMed ID: 16198561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Small molecule antagonists of the CCR2b receptor. Part 2: Discovery process and initial structure-activity relationships of diamine derivatives.
    Moree WJ; Kataoka K; Ramirez-Weinhouse MM; Shiota T; Imai M; Sudo M; Tsutsumi T; Endo N; Muroga Y; Hada T; Tanaka H; Morita T; Greene J; Barnum D; Saunders J; Kato Y; Myers PL; Tarby CM
    Bioorg Med Chem Lett; 2004 Nov; 14(21):5413-6. PubMed ID: 15454236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chapter 12. The use of receptor homology modeling to facilitate the design of selective chemokine receptor antagonists.
    Carter PH; Tebben AJ
    Methods Enzymol; 2009; 461():249-79. PubMed ID: 19480923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of novel series of human CCR1 antagonists.
    Xie YF; Sircar I; Lake K; Komandla M; Ligsay K; Li J; Xu K; Parise J; Schneider L; Huang D; Liu J; Sakurai N; Barbosa M; Jack R
    Bioorg Med Chem Lett; 2008 Mar; 18(6):2215-21. PubMed ID: 18329267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Core exploration in optimization of chemokine receptor CCR4 antagonists.
    Purandare AV; Wan H; Somerville JE; Burke C; Vaccaro W; Yang X; McIntyre KW; Poss MA
    Bioorg Med Chem Lett; 2007 Feb; 17(3):679-82. PubMed ID: 17098428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis, and progress toward optimization of potent small molecule antagonists of CC chemokine receptor 8 (CCR8).
    Ghosh S; Elder A; Guo J; Mani U; Patane M; Carson K; Ye Q; Bennett R; Chi S; Jenkins T; Guan B; Kolbeck R; Smith S; Zhang C; LaRosa G; Jaffee B; Yang H; Eddy P; Lu C; Uttamsingh V; Horlick R; Harriman G; Flynn D
    J Med Chem; 2006 May; 49(9):2669-72. PubMed ID: 16640325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel CCR1 antagonists with improved metabolic stability.
    Brown MF; Avery M; Brissette WH; Chang JH; Colizza K; Conklyn M; DiRico AP; Gladue RP; Kath JC; Krueger SS; Lira PD; Lillie BM; Lundquist GD; Mairs EN; McElroy EB; McGlynn MA; Paradis TJ; Poss CS; Rossulek MI; Shepard RM; Sims J; Strelevitz TJ; Truesdell S; Tylaska LA; Yoon K; Zheng D
    Bioorg Med Chem Lett; 2004 May; 14(9):2175-9. PubMed ID: 15081003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Piperazinyl CCR1 antagonists--optimization of human liver microsome stability.
    Brown MF; Bahnck KB; Blumberg LC; Brissette WH; Burrell SA; Driscoll JP; Fedeles F; Fisher MB; Foti RS; Gladue RP; Guzman-Martinez A; Hayward MM; Lira PD; Lillie BM; Lu Y; Lundquist GD; McElroy EB; McGlynn MA; Paradis TJ; Poss CS; Roache JH; Shavnya A; Shepard RM; Trevena KA; Tylaska LA
    Bioorg Med Chem Lett; 2007 Jun; 17(11):3109-12. PubMed ID: 17383873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diaryl substituted pyrazoles as potent CCR2 receptor antagonists.
    Pinkerton AB; Huang D; Cube RV; Hutchinson JH; Struthers M; Ayala JM; Vicario PP; Patel SR; Wisniewski T; DeMartino JA; Vernier JM
    Bioorg Med Chem Lett; 2007 Feb; 17(3):807-13. PubMed ID: 17088058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 1-(4-Phenylpiperazin-1-yl)-2-(1H-pyrazol-1-yl)ethanones as novel CCR1 antagonists.
    Pennell AM; Aggen JB; Sen S; Chen W; Xu Y; Sullivan E; Li L; Greenman K; Charvat T; Hansen D; Dairaghi DJ; Wright JJ; Zhang P
    Bioorg Med Chem Lett; 2013 Mar; 23(5):1228-31. PubMed ID: 23374868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure function differences in nonpeptide CCR1 antagonists for human and mouse CCR1.
    Onuffer J; McCarrick MA; Dunning L; Liang M; Rosser M; Wei GP; Ng H; Horuk R
    J Immunol; 2003 Feb; 170(4):1910-6. PubMed ID: 12574358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis, and discovery of a novel CCR1 antagonist.
    Naya A; Sagara Y; Ohwaki K; Saeki T; Ichikawa D; Iwasawa Y; Noguchi K; Ohtake N
    J Med Chem; 2001 Apr; 44(9):1429-35. PubMed ID: 11311066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BX-471 Berlex.
    Elices MJ
    Curr Opin Investig Drugs; 2002 Jun; 3(6):865-9. PubMed ID: 12137405
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery and SAR of trisubstituted thiazolidinones as CCR4 antagonists.
    Allen S; Newhouse B; Anderson AS; Fauber B; Allen A; Chantry D; Eberhardt C; Odingo J; Burgess LE
    Bioorg Med Chem Lett; 2004 Apr; 14(7):1619-24. PubMed ID: 15026036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of 3-piperidinyl-1-cyclopentanecarboxamide as a novel scaffold for highly potent CC chemokine receptor 2 antagonists.
    Yang L; Butora G; Jiao RX; Pasternak A; Zhou C; Parsons WH; Mills SG; Vicario PP; Ayala JM; Cascieri MA; MacCoss M
    J Med Chem; 2007 May; 50(11):2609-11. PubMed ID: 17461566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 4-Amino-2-alkyl-butyramides as small molecule CCR2 antagonists with favorable pharmacokinetic properties.
    Butora G; Morriello GJ; Kothandaraman S; Guiadeen D; Pasternak A; Parsons WH; MacCoss M; Vicario PP; Cascieri MA; Yang L
    Bioorg Med Chem Lett; 2006 Sep; 16(18):4715-22. PubMed ID: 16870431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.